title: Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer.
abstract: OBJECTIVE
  To determine if oncogene overexpression in patients with advanced epithelial ovarian cancer correlates with survival.
  
  
  METHODS
  Twenty-two women with stage III ovarian cancer, observed for a median of 66 (range 48-204) months were compared with 30 with a median survival of 18 (range 2-28) months. Using immunocytochemistry, tumors were immunostained for overexpression of p53, c-erb-B-2, and epidermal growth factor receptor and were evaluated quantitatively for expression of estrogen receptor, progesterone receptor, and Ki-67 antigen, a marker of cellular proliferation.
  
  
  RESULTS
  The median age of long-term survivors was 52 (range 30-76) years compared with 55 (range 36-80) years for short-term survivors. Optimal cytoreduction was achieved in 11 of the 22 long-term survivors compared with seven of the 30 short-term survivors, a significant difference (P=.05). The average level of Ki-67 expression was 43% in long-term survivors and 64% in short-term survivors (P=.007). Overexpression of p53 was seen in 54% of long-term survivors and 80% of short-term survivors (P=.05). A combination of Ki-67 level of 50% or greater plus p53 overexpression was seen in 22% of long-term survivors compared with 68% of short-term survivors (P=.005). Epidermal growth factor receptor, c-erb-B-2, estrogen receptor, and progesterone receptor statuses did not differ significantly between the two groups.
  
  
  CONCLUSIONS
  Markers that did not correlate with survival included the hormone receptors, estrogen receptor and progesterone receptor, and the oncogenes, c-erb-B-2 and epidermal growth factor receptor. Long-term survivors with advanced ovarian cancer were more likely to have had an optimal cytoreduction and lower levels of Ki-67 antigen expression and were less likely to overexpress p53 than were short-term survivors.
authors.affiliation: University of Washington Medical Center, Seattle 98195, USA. bgoff@u.washington.edu
authors.forename: B A
authors.initials: BA
authors.lastname: Goff
authors.forename: H G
authors.initials: HG
authors.lastname: Muntz
authors.forename: B E
authors.initials: BE
authors.lastname: Greer
authors.forename: H K
authors.initials: HK
authors.lastname: Tamimi
authors.forename: A M
authors.initials: AM
authors.lastname: Gown
mesh_terms: D000328:Adult; D000368:Aged; D002291:Carcinoma, Papillary / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D018734:Genes, erbB-2 / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D008875:Middle Aged; D009367:Neoplasm Staging; D009857:Oncogenes / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality* / Q000473:pathology; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D015996:Survival Rate; D013997:Time Factors
chemical_list: D019394:Ki-67 Antigen; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D066246:ErbB Receptors